PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus

J Diabetes Res. 2018 Aug 30:2018:3984797. doi: 10.1155/2018/3984797. eCollection 2018.

Abstract

Objective: Inflammation plays a major role in albuminuria in type 2 diabetes mellitus (T2DM). Our previous studies have shown that the expression of vitamin D receptor (VDR) is downregulated in T2DM which is closely associated with the severity of albuminuria. In this study, we investigated the expression of anti-inflammatory cytokine protein tyrosine phosphatase nonreceptor type 2 (PTPN2) in T2DM and explored its relationship to albuminuria and VDR.

Methods: 101 T2DM patients were divided into three groups based on urinary albumin-to-creatinine ratio (uACR): normal albuminuria (uACR < 30 mg/g, n = 29), microalbuminuria (30 mg/g ≤ uACR < 300 mg/g, n = 34), and macroalbuminuria (uACR ≥ 300 mg/g, n = 38). Thirty healthy individuals were included as controls. Serum was analyzed for PTPN2 and IL-6 expression, and peripheral blood mononuclear cells (PBMCs) were analyzed for PTPN2 and VDR expression. THP-1 cells were incubated with high glucose and further treated with or without paricalcitol, a vitamin D analog. The levels of PTPN2, VDR, IL-6, TNFα, and MCP-1 were analyzed. In addition, anti-inflammatory activities of PTPN2 were further explored in THP-1 cells stimulated with high glucose after PTPN2 silencing or overexpression.

Results: PTPN2 expression was downregulated in T2DM with the lowest level observed in macroalbuminuria patients. PTPN2 level positively correlated with VDR but negatively correlated with uACR and IL-6. When stimulated with high glucose, there was an increase in inflammatory factors and a decrease in PTPN2 expression. Treatment with paricalcitol reversed these effects. However, paricalcitol failed to exert anti-inflammatory effects in the setting of PTPN2 knockdown. Thus, low levels of PTPN2 aggravated glucose-stimulated inflammation, while high levels of PTPN2 reduced it.

Conclusion: PTPN2, an anti-inflammatory factor regulated by VDR, was reduced in T2DM CKD stages 1-2. Taken together, our results suggest that therapeutic strategies that enhance PTPN2 may be beneficial for controlling inflammation in T2DM.

MeSH terms

  • Adult
  • Aged
  • Albuminuria / blood
  • Albuminuria / diagnosis
  • Albuminuria / etiology*
  • Albuminuria / urine
  • Biomarkers / blood
  • Biomarkers / urine
  • Case-Control Studies
  • Chemokine CCL2 / metabolism
  • Creatinine / urine
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / urine
  • Diabetic Nephropathies / blood
  • Diabetic Nephropathies / diagnosis
  • Diabetic Nephropathies / etiology*
  • Diabetic Nephropathies / urine
  • Down-Regulation
  • Female
  • Humans
  • Inflammation / blood
  • Inflammation / diagnosis
  • Inflammation / etiology*
  • Inflammation / urine
  • Interleukin-6 / blood
  • Male
  • Middle Aged
  • Monocytes / metabolism
  • Protein Tyrosine Phosphatase, Non-Receptor Type 2 / blood*
  • Protein Tyrosine Phosphatase, Non-Receptor Type 2 / genetics
  • Receptors, Calcitriol / blood
  • Receptors, Calcitriol / deficiency*
  • Renal Insufficiency, Chronic / blood
  • Renal Insufficiency, Chronic / diagnosis
  • Renal Insufficiency, Chronic / etiology*
  • Renal Insufficiency, Chronic / urine
  • THP-1 Cells
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Biomarkers
  • CCL2 protein, human
  • Chemokine CCL2
  • IL6 protein, human
  • Interleukin-6
  • Receptors, Calcitriol
  • Tumor Necrosis Factor-alpha
  • VDR protein, human
  • Creatinine
  • PTPN2 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 2